Figure 1.

(A) Bar chart showing the proportion of total and radiologically evaluable axitinib dose escalation events (DEEs) that were made for reasons for progressive disease (PD), a mixed radiological response (MR) or drug tolerance and a clinical need to dose escalate (T and CN).(B) Bar chart showing the radiological outcomes (results) for evaluable DEEs for all DEEs (ALL), and those that were made for reasons for PD, an MR or drug tolerance and a clinical need to dose escalate (T and CN). MR, mixed response; PD, progressive disease; PR, partial response; SD, stable disease.